TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain

NCT ID: NCT01066520

Last Updated: 2014-01-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

449 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine the efficacy of Traumeel S (both ointment and gel) compared to another antiinflammatory drug called Diclofenac in patients with a sprained ankle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study objective is the confirmatory proof of efficacy for Traumeel® S topical treatment, both ointment and gel, as compared to diclofenac topical treatment for patients with ankle sprain. In addition tolerability/safety of both drug preparations is to be compared, so that the benefit-risk relation can be determined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sprain of Ankle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Traumeel S ointment

Traumeel S ointment 2 g, 3 times daily topical during 14 days

Group Type EXPERIMENTAL

Traumeel S ointment

Intervention Type DRUG

2 g, 3 times daily topical during 14 days

Traumeel S gel

Traumeel S gel 2 g, 3 times daily topical during 14 days

Group Type EXPERIMENTAL

Traumeel S gel

Intervention Type DRUG

2 g, 3 times daily topical during 14 days

Diclofenac gel

Diclofenac gel 2 g, 3 times daily topical during 14 days

Group Type ACTIVE_COMPARATOR

Diclofenac gel

Intervention Type DRUG

2 g, 3 times daily topical during 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Traumeel S ointment

2 g, 3 times daily topical during 14 days

Intervention Type DRUG

Traumeel S gel

2 g, 3 times daily topical during 14 days

Intervention Type DRUG

Diclofenac gel

2 g, 3 times daily topical during 14 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Traumeel S ointment, Traumeel S gel, Diclofenac gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Athletes with an acute unilateral ankle sprain of the lateral ligaments of the ankle joint both male and female
* Moderate (30-60 mm) to severe (\>60 mm) pain according to the patient's assessment of ankle pain visual analogue scale (VAS) on weight bearing, unable to perform normal training / sports activities
* 18 - 40 years of age
* injury occurred within 24 hours of the first dose of study medication
* Willing and able to give written informed consent
* Available for the duration of the study

Exclusion Criteria

* Similar injury affecting the same joint within the past 6 months
* bilateral ankle injury
* bed rest, hospitalization, surgery use of a non-removable rigid cast
* Clinically important abnormality for screening laboratory tests
* Debilitating acute or chronic illness
* Use of corticosteroids in the previous 8 weeks, any analgesics in the previous 6 hours, or 24 hours in case of long-acting NSAID, COX-2 specific inhibitors, or tramadol
* History of sensitivity to any component of the study drugs
* Unwilling or unable to comply with all the requirements of the protocol
* Participation in other studies within 4 weeks prior to study entry and or during the study participation
* Current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study result
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biologische Heilmittel Heel GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carlos Gonzalez de Vega, MD

Role: STUDY_CHAIR

National Coordinating Investigator

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MEDYR Medicina Deportiva y Rehabilitación

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Gonzalez de Vega C, Speed C, Wolfarth B, Gonzalez J. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract. 2013 Oct;67(10):979-89. doi: 10.1111/ijcp.12219. Epub 2013 Jul 25.

Reference Type DERIVED
PMID: 23889885 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12219/full

Primary publication paper International Journal of Clinical Practice online

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-007939-41

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TRS-ESP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.